It is also not correct to discount other treatments by saying they don't have to demonstrate superior efficacy to them. The trial will need to show overall survival benefit. The patients will have the option before and after the trial (those surviving) to try other drugs which obviously effects survival rates.
Ann: June 2018 Quarterly Report, page-19
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.025(1.53%) |
Mkt cap ! $282.7M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.58 | $350.6K | 215.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 2493 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |